Genetic polymorphisms, such as catalase gene variations and toll‐like receptor polymorphisms, along with stem cell targets such as melanocytes derived from stem cells, have been implicated in vitiligo onset and possible treatment. The gene discussed is CAT; the disease is vitiligo.